Cardiometabolic Disorders News

A set of newly identified genetic risk factors tied to the development of type 2 diabetes could eventually lead to the discovery of genotypes that allow providers to identify people at highest risk for complications.

ATLANTA — New results from the TACTiC trial show the promise of technology to help individuals appropriately determine if they qualify for statin therapy without a prescription.

ATLANTA — In the TACT2 trial, chelation therapy reduced levels of lead in the blood but did not improve cardiovascular outcomes for adults with diabetes and a prior heart attack.

ATLANTA — Adults with obesity, HF with preserved ejection fraction and type 2 diabetes saw marked improvements in HF symptoms and physical function with semaglutide 2.4 mg compared with placebo, despite less than typical weight loss.

ATLANTA — Monthly administration of subcutaneous olezarsen substantially reduced triglyceride levels compared with placebo among patients with predominantly moderate hypertriglyceridemia and elevated CV risk, according to new phase 2 data.

ATLANTA — In the EMPACT-MI trial, empagliflozin treatment soon after an acute MI did not significantly lower risk for HF hospitalization or death from any cause compared with placebo among patients with increased risk for HF.

Adults with hyperthyroidism who undergo surgery or receive radioactive iodine therapy have a lower risk for major adverse cardiovascular events than those receiving antithyroid drugs, according to data published in JAMA Network Open.

The impact of social determinants of health on cardiovascular risk factors may vary across Asian American subgroups such as Filipino, Asian Indian, Chinese and other Asian populations, researchers reported.

Adults with type 2 diabetes have a reduction in overall health care costs after bariatric surgery, regardless of whether they underwent gastric bypass or sleeve gastrectomy, according to study findings published in Obesity.